Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing

Liu, Heng; Vries-Idema, Jacqueline de; Veer, Wouter ter; Wilschut, Jan; Huckriede, Anke

doi:10.1007/s00430-013-0313-2

Cited by 15 publications

(12 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additional components are included to optimize particle assembly and stability and to enhance immunostimulatory effects [Moser et al 2013]. GPI-0100, a saponin derivative, enhanced immunogenicity and protective efficacy of a virosomal influenza vaccine, providing full protection of infected mice at extremely low antigen doses [Liu et al 2013]. A combination of reconstituted respiratory syncytial virus (RSV) envelopes with incorporated MPLA (RSV-MPLA) virosomes was studied by Kamphuis and colleagues in enhanced respiratory disease prone rats.…”

Section: Archaeosomesmentioning

confidence: 99%

Liposomes as vaccine delivery systems: a review of the recent advances

Schwendener

2014

Therapeutic Advances in Vaccines

432

309

View full text Add to dashboard Cite

Liposomes and liposome-derived nanovesicles such as archaeosomes and virosomes have become important carrier systems in vaccine development and the interest for liposome-based vaccines has markedly increased. A key advantage of liposomes, archaeosomes and virosomes in general, and liposome-based vaccine delivery systems in particular, is their versatility and plasticity. Liposome composition and preparation can be chosen to achieve desired features such as selection of lipid, charge, size, size distribution, entrapment and location of antigens or adjuvants. Depending on the chemical properties, water-soluble antigens (proteins, peptides, nucleic acids, carbohydrates, haptens) are entrapped within the aqueous inner space of liposomes, whereas lipophilic compounds (lipopeptides, antigens, adjuvants, linker molecules) are intercalated into the lipid bilayer and antigens or adjuvants can be attached to the liposome surface either by adsorption or stable chemical linking. Coformulations containing different types of antigens or adjuvants can be combined with the parameters mentioned to tailor liposomal vaccines for individual applications. Special emphasis is given in this review to cationic adjuvant liposome vaccine formulations. Examples of vaccines made with CAF01, an adjuvant composed of the synthetic immune-stimulating mycobacterial cordfactor glycolipid trehalose dibehenate as immunomodulator and the cationic membrane forming molecule dimethyl dioctadecylammonium are presented. Other vaccines such as cationic liposome-DNA complexes (CLDCs) and other adjuvants like muramyl dipeptide, monophosphoryl lipid A and listeriolysin O are mentioned as well. The field of liposomes and liposome-based vaccines is vast. Therefore, this review concentrates on recent and relevant studies emphasizing current reports dealing with the most studied antigens and adjuvants, and pertinent examples of vaccines. Studies on liposome-based veterinary vaccines and experimental therapeutic cancer vaccines are also summarized.

show abstract

Section: Archaeosomesmentioning

confidence: 99%

Liposomes as vaccine delivery systems: a review of the recent advances

Schwendener

2014

Therapeutic Advances in Vaccines

432

309

View full text Add to dashboard Cite

show abstract

“…Influenza virosomes were prepared from inactivated NC99 influenza virus according to the protocol published before with some modification . Briefly, DOGS‐NTA‐Ni or DOGS‐NTA, dissolved in chloroform, were mixed with MPLA, dissolved in ethanol, at a ratio of 100 nmol DOGS:100 μg MPLA.…”

Section: Methodsmentioning

confidence: 99%

“…Serum antibodies against the surface proteins of HK68 virus and antibody against NP protein were detected by ELISA as previously published . Briefly, 0.3 μg of HK68 subunit vaccine prepared as before or 0.3 μg of his‐tagged NP protein was coated on 96‐well plates overnight in 100 μl of coating buffer (0.05 M carbonate bicarbonate, pH 9.6–9.8).…”

Section: Methodsmentioning

confidence: 99%

Monophosphoryl Lipid A‐Adjuvanted Virosomes with Ni‐Chelating Lipids for Attachment of Conserved Viral Proteins as Cross‐Protective Influenza Vaccine

Dong

Bhide

Marsman

et al. 2018

Biotechnology Journal

Self Cite

View full text Add to dashboard Cite

Induction of CD8 cytotoxic T cells (CTLs) to conserved internal influenza antigens, such as nucleoprotein (NP), is a promising strategy for the development of cross-protective influenza vaccines. However, influenza NP protein alone cannot induce CTL immunity due to its low capacity to activate antigen-presenting cells (APCs) and get access to the MHC class I antigen processing pathway. To facilitate the generation of NP-specific CTL immunity the authors develop a novel influenza vaccine consisting of virosomes with the Toll-like receptor 4 (TLR4) ligand monophosphoryl lipid A (MPLA) and the metal-ion-chelating lipid DOGS-NTA-Ni incorporated in the membrane. In vitro, virosomes with incorporated MPLA induce stronger activation of APCs than unadjuvanted virosomes. Virosomes modified with DOGS-NTA-Ni show high conjugation efficacy for his-tagged proteins and facilitate efficient uptake of conjugated proteins by APCs. Immunization of mice with MPLA-adjuvanted virosomes with attached NP results in priming of NP-specific CTLs while MPLA-adjuvanted virosomes with admixed NP are inefficient in priming CTLs. Both vaccines induce equally high titers of NP-specific antibodies. When challenged with heterosubtypic influenza virus, mice immunized with virosomes with attached or admixed NP are protected from severe weight loss. Yet, unexpectedly, they show more weight loss and more severe disease symptoms than mice immunized with MPLA-virosomes without NP. Taken together, these results indicate that virosomes with conjugated antigen and adjuvant incorporated in the membrane are effective in priming of CTLs and eliciting antigen-specific antibody responses in vivo. However, for protection from influenza infection NP-specific immunity appears not to be advantageous.

show abstract

“…Virosomes recognize and bind to the same receptors that are utilized in case of a natural viral infection. Sialic acid receptors, for instance, are utilized by the influenza virosomes [62]. After the cell receptor recognition by the virus, fusion of viral and endosomal membrane is observed [38].…”

Section: Virosome-cell Interactionmentioning

confidence: 99%

Virosomes-Hybrid Drug Delivery Systems

Kazi¹

2013

J Antivir Antiretrovir

View full text Add to dashboard Cite

The development of safe and effective models for the delivery of any prophylactic or therapeutic agent remains an uphill task for pharmaceutical formulation developers. Drug molecules, nucleic acids, carbohydrates, proteins and a variety of other biological and chemical entities are used for attaining pharmacological benefits. However, the major challenge remains in the delivery of these agents to the specific site of action in a time-efficient manner. Among the many drug delivery systems developed, the nano scale technology of virosomes tends to present an established system of delivering the therapeutic agents to the site of pharmacological action. Virosomes are lipid bilayer, unilamellar structures that present viral protein on their surface. They are safe, biocompatible and biodegradable structures that can achieve ideal pharmacological profile once administered into the body. Tissue targeting, immune activation and potentiation are the chief advantages that make them efficient prophylactic and therapeutic agents. The review presents the biopharmaceutical applications of virosomes and the immunological and pharmaceutical considerations that make them efficient agents for targeting spatiotemporal parameters in the body.

show abstract

Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing

Cited by 15 publications

References 42 publications

Liposomes as vaccine delivery systems: a review of the recent advances

Liposomes as vaccine delivery systems: a review of the recent advances

Monophosphoryl Lipid A‐Adjuvanted Virosomes with Ni‐Chelating Lipids for Attachment of Conserved Viral Proteins as Cross‐Protective Influenza Vaccine

Virosomes-Hybrid Drug Delivery Systems

Contact Info

Product

Resources

About